论文部分内容阅读
将52例使用诺和灵30R未达标的T2DM患者分为2组,一组调整诺和灵30R的用量;另一组改用诺和锐30每天3次注射治疗12周。结果:诺和锐30治疗组HbA1c、空腹血糖(FPG)、餐后2小时血糖(h2PG)控制、血糖波动、低血糖发生率优于诺和灵30R组(P<0.01、0.05);胰岛素用量无显著性差异(P>0.05)。结论:诺和锐30每天3次治疗T2DM控制HbA1c、FPG、h2PG、血糖波动的范围、低血糖的发生率优于诺和灵30R。
Fifty-two patients with T2DM who did not achieve compliance with Noropen 30R were divided into two groups. One group adjusted the dosage of Novolin 30R. The other group used NovoRay 30 twice a day for 12 weeks. Results: The levels of HbA1c, fasting blood glucose (FPG) and 2 hours postprandial blood glucose (h2PG) were significantly higher in Novo-Rui 30 treatment group than those in Noren 30R group (P <0.01,0.05) No significant difference (P> 0.05). CONCLUSION: Novo-Rui 30 treatment of T2DM three times a day to control the range of HbA1c, FPG, h2PG, blood glucose fluctuations, the incidence of hypoglycemia superior to noradren 30R.